FENRIS BIO AS
Operating
Utvikle nye medisiner mot kroniske sykdommer.
Utvikling av ny medisin.
Organization
- CEO
- Chairman of the board
- ØR
Øivind Resch1961
- Years since formation
- 1 year
- since Mar 6, 2025
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 0
Ownership
- Number of shares and share classes
- 34,796
- 1 share class
- Total number of shareholders
- 10
- 8 companies, 2 persons
Financials
- Annual total result 2025
- -1,452,890
- NOK
- Total equity 2025
- -628,458
- NOK
Last update: Jul 27, 2026
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
| Managing Director/CEO | 25.43 % indirectly |
Board
| Name | Role | Shares |
|---|---|---|
ØR 1961 | Chairman | 25.43 % indirectly |
| Board Member | 25.43 % indirectly |
Others
| Name | Role | Shares |
|---|---|---|
| Accountant | - |
Top 10 individual shareholders
| Name | Role | Shares |
|---|---|---|
| Managing Director/CEO, Board Member | 25.43 % indirectly | |
ØR 1961 | Chairman | 25.43 % indirectly |
| - | 12.93 % directly | |
OR | - | 9.47 % indirectly |
| - | 8.62 % indirectly | |
| - | 4.31 % indirectly | |
MS 1988 | - | 4.31 % indirectly |
MØ | - | 1.72 % indirectly |
TB 1964 | - | 1.08 % indirectly |
Last update: Jun 19, 2025
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| Ordinary shares | 8,850 | 25.43 % | |
| Ordinary shares | 8,850 | 25.43 % | |
| Ordinary shares | 4,500 | 12.93 % | |
| Ordinary shares | 3,296 | 9.47 % | |
| Ordinary shares | 3,000 | 8.62 % | |
| Ordinary shares | 3,000 | 8.62 % | |
| Ordinary shares | 1,650 | 4.74 % | |
| Ordinary shares | 735 | 2.11 % | |
| Ordinary shares | 600 | 1.72 % | |
| Ordinary shares | 315 | 0.91 % |
Last update: Sep 25, 2026
Financials
in NOK
Summary
| Year | 2025 |
|---|---|
Total operating income | 0 |
Annual Total Result | -1,452,890 |
Total assets | 1,767,387 |
Total liabilities | 2,395,844 |
Total equity | -628,458 |
P&L
| Year | 2025 |
|---|---|
Total operating income | 0 |
Total operating costs | 1,445,130 |
Operating result | -1,445,130 |
Financial income/costs | -7,759 |
Profit before tax | -1,452,890 |
Total tax & extraordinary income/cost | 0 |
Annual Total Result | -1,452,890 |
Balance overview
| Year | 2025 |
|---|---|
Total fixed assets | 0 |
Total current assets | 1,767,387 |
Total assets | 1,767,387 |
Short term debt | 2,395,844 |
Long term debt | 0 |
Total liabilities | 2,395,844 |
Contributed capital | 824,432 |
Retained earnings | -1,452,890 |
Total equity | -628,458 |
Total equity and liabilities | 1,767,387 |
Classification
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification